Oral Health Group

Biostage Successfully Regenerates Esophagus in Groundbreaking Pre-Clinical Work with Mayo Clinic; Data Provides ‘Proof of Concept’ to Seek FDA Approval for Clinical Trials

May 13, 2016
by Oral Health

BiostageBiostage, Inc. (BSTG), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea today announced significant, pre-clinical data, including the complete regeneration of a segment of the esophagus, from its collaborative large-animal study of its Cellspan™ organ implants with Mayo Clinic. Biostage will review this research in a conference call today at 9:00 am ET (details below).

Groundbreaking Results:
The study has clearly demonstrated in a predictive large-animal model the ability of Biostage Cellspan organ implants to successfully stimulate the regeneration of sections of esophagus that had been surgically removed for the study. Cellspan esophageal implants, consisting of a proprietary biocompatible synthetic scaffold seeded with the recipient animal’s own stem cells, were surgically implanted in place of the esophagus section that had been removed.

Study animals were returned to a solid diet two weeks after implantation surgery. The scaffolds, which are intended to be in place only temporarily, were later retrieved via the animal’s mouth in a non-surgical endoscopic procedure.

To continue reading, please visit: http://www.prnewswire.com/news-releases/biostage-successfully-regenerates-esophagus-in-groundbreaking-pre-clinical-work-with-mayo-clinic-data-provides-proof-of-concept-to-seek-fda-approval-for-clinical-trials-300267404.html.

Print this page


Have your say:

Your email address will not be published.